English
Home > Products > 86-74-8

China 86-74-8 Factory

We'll make each individual effort to become exceptional and ideal, and speed up our steps for standing inside the rank of worldwide top-grade and high-tech enterprises for 86-74-8,CAS NO 86-74-8,Carbazole, We warmly welcome friends from all walks of life to cooperate with us.
86-74-8, Satisfaction and good credit to every customer is our priority. We focus on every detail of order processing for customers till they have received safe and sound products with good logistics service and economical cost. Depending on this, our products and solutions are sold very well in the countries in Africa, the Mid-East and Southeast Asia.

Related Products

Hot Products

  • Bortezomib intermediates II

    Bortezomib intermediates II

    Product Name:Bortezomib intermediates II
    Molecular Formula:C24H38BClN2O3
    Molecular Weight:448.83412
    CAS Registry Number:205393-21-1
  • 1,3-Dibromo-5-chlorobenzene

    1,3-Dibromo-5-chlorobenzene

    Product Name:1,3-Dibromo-5-chlorobenzene
    Molecular Formula:C6H3Br2Cl
    Molecular Weight:270.35
    CAS Registry Number:14862-52-3
  • 2-Hydrazinopyrazine

    2-Hydrazinopyrazine

    Product Name:2-Hydrazinopyrazine
    Molecular Formula:C4H6N4
    Molecular Weight:110.12
    CAS Registry Number:54608-52-5
  • 2,5-Dichloroaniline

    2,5-Dichloroaniline

    Product Name:2,5-Dichloroaniline
    Molecular Formula:C6H5Cl2N
    Molecular Weight:162.02
    CAS Registry Number:95-82-9
  • L-Hydroxyproline

    L-Hydroxyproline

    Product Name:L-Hydroxyproline
    Molecular Formula:C5H9NO3
    Molecular Weight:131.13
    CAS Registry Number:51-35-4
  • 4-Amino-3-fluorophenol

    4-Amino-3-fluorophenol

    Product Name:4-Amino-3-fluorophenol
    Molecular Formula:C6H6FNO
    Molecular Weight:127.12
    CAS Registry Number:399-95-1
  • Related Blog
  • Reviews

  • What is the difference between API and FDF in pharma？

    In the pharmaceutical industry, you might hear the terms “FDF” and “API” frequently used in reference to products. We surely understand this type of jargon, but we certainly can see how the general public would feel overwhelmed looking at those kinds of terminology abbreviations. This article is for explaining the difference between API and FDF. For reference, they mean, respectively, “finished dosage form” and “active pharmaceutical ingredient.”

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • Tofacitinib More Effective, Alone and in Combinations, than Non-biologic DMARDS

    Tofacitinib (marketed under the brand name Xeljanz) is an oral Janus kinase inhibitor currently approved for the treatment of RA. It was developed in a unique public-private partnership between the National Institutes of Health...

  • TOP 8 Linezolid intermediate maker

    Sandoo Pharmaceuticals and Chemicals Co.,Ltd was established in 2009, with a creative and active team, located in Ningbo, China. We have been specialized in exporting and importing pharmaceutical intermediates and chemical products as well as API for more than 10 years, covering more than 10 countries.

  • What Is Misoprostol Used For?

    Misoprostol, a derivative of prostaglandin E1, can be used in the treatment of duodenal ulcer, the prevention of anti-inflammatory induced peptic ulcer and the prevention of early pregnancy.It has the function of inhibiting the secretion of gastric acid and preventing the formation of ulcer, thus protecting the gastric mucosa...

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Related Search

CAS NO 86-74-8

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept